Oluyemisi Rafiat Soetan, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 133 Sumner Ave, Plainfield, NJ 07062 Phone: 973-493-6606 |
Marlene Morgan-douglas, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1408 Linbarger Ave, Plainfield, NJ 07062 Phone: 800-950-6066 |
Jessica Ruiz, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 31 Mariners Pl, Plainfield, NJ 07063 Phone: 800-950-6066 |
Dawn Washington, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1229 Galbraith Pl, Plainfield, NJ 07063 Phone: 800-950-6066 |
Emma Miller, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 715 South Ave, Plainfield, NJ 07062 Phone: 908-357-8582 |
News Archive
Sosei Group Corporation confirms the information released today by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler (glycopyrronium/NVA237) 44 mcg delivered dose (50 mcg glycopyrronium per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
New research from Roswell Park Cancer Institute offers clinicians treating patients with advanced liver cancer a way of determining which patients may benefit most from the targeted therapy sorafenib.
The reactivation of telomerase is a key mechanism in the unrestricted growth of cancer cells. Malignant pleural mesothelioma (MPM) is a form of cancer originating from the mesothelium, a cell layer covering the lungs and the inside of the chest wall.
When governments and institutions deploy epidemic forecast models when facing an outbreak, they sometimes fail to factor in human behavior and over-allocate precious resources as a result.
Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.
› Verified 1 days ago